Cargando…
Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer Health
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437562/ https://www.ncbi.nlm.nih.gov/pubmed/32885140 http://dx.doi.org/10.1097/HS9.0000000000000370 |
| _version_ | 1783572646543228928 |
|---|---|
| author | Wester, Ruth Zweegman, Sonja van der Holt, Bronno Kersten, Marie José Vellenga, Edo van Marwijk-Kooy, Marinus Asselbergs, Emelie de Weerdt, Okke Minnema, Monique C. Lonergan, Sarah Palumbo, Antonio Broijl, Annemiek Sonneveld, Pieter |
| author_facet | Wester, Ruth Zweegman, Sonja van der Holt, Bronno Kersten, Marie José Vellenga, Edo van Marwijk-Kooy, Marinus Asselbergs, Emelie de Weerdt, Okke Minnema, Monique C. Lonergan, Sarah Palumbo, Antonio Broijl, Annemiek Sonneveld, Pieter |
| author_sort | Wester, Ruth |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7437562 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Wolters Kluwer Health |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74375622020-09-02 Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial Wester, Ruth Zweegman, Sonja van der Holt, Bronno Kersten, Marie José Vellenga, Edo van Marwijk-Kooy, Marinus Asselbergs, Emelie de Weerdt, Okke Minnema, Monique C. Lonergan, Sarah Palumbo, Antonio Broijl, Annemiek Sonneveld, Pieter Hemasphere Letter Wolters Kluwer Health 2020-08-12 /pmc/articles/PMC7437562/ /pubmed/32885140 http://dx.doi.org/10.1097/HS9.0000000000000370 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
| spellingShingle | Letter Wester, Ruth Zweegman, Sonja van der Holt, Bronno Kersten, Marie José Vellenga, Edo van Marwijk-Kooy, Marinus Asselbergs, Emelie de Weerdt, Okke Minnema, Monique C. Lonergan, Sarah Palumbo, Antonio Broijl, Annemiek Sonneveld, Pieter Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial |
| title | Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial |
| title_full | Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial |
| title_fullStr | Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial |
| title_full_unstemmed | Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial |
| title_short | Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial |
| title_sort | carfilzomib combined with thalidomide and low-dose dexamethasone for remission induction and consolidation in newly diagnosed transplant eligible patients with multiple myeloma: 8 vs 4 induction cycles; the carthadex trial |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437562/ https://www.ncbi.nlm.nih.gov/pubmed/32885140 http://dx.doi.org/10.1097/HS9.0000000000000370 |
| work_keys_str_mv | AT westerruth carfilzomibcombinedwiththalidomideandlowdosedexamethasoneforremissioninductionandconsolidationinnewlydiagnosedtransplanteligiblepatientswithmultiplemyeloma8vs4inductioncyclesthecarthadextrial AT zweegmansonja carfilzomibcombinedwiththalidomideandlowdosedexamethasoneforremissioninductionandconsolidationinnewlydiagnosedtransplanteligiblepatientswithmultiplemyeloma8vs4inductioncyclesthecarthadextrial AT vanderholtbronno carfilzomibcombinedwiththalidomideandlowdosedexamethasoneforremissioninductionandconsolidationinnewlydiagnosedtransplanteligiblepatientswithmultiplemyeloma8vs4inductioncyclesthecarthadextrial AT kerstenmariejose carfilzomibcombinedwiththalidomideandlowdosedexamethasoneforremissioninductionandconsolidationinnewlydiagnosedtransplanteligiblepatientswithmultiplemyeloma8vs4inductioncyclesthecarthadextrial AT vellengaedo carfilzomibcombinedwiththalidomideandlowdosedexamethasoneforremissioninductionandconsolidationinnewlydiagnosedtransplanteligiblepatientswithmultiplemyeloma8vs4inductioncyclesthecarthadextrial AT vanmarwijkkooymarinus carfilzomibcombinedwiththalidomideandlowdosedexamethasoneforremissioninductionandconsolidationinnewlydiagnosedtransplanteligiblepatientswithmultiplemyeloma8vs4inductioncyclesthecarthadextrial AT asselbergsemelie carfilzomibcombinedwiththalidomideandlowdosedexamethasoneforremissioninductionandconsolidationinnewlydiagnosedtransplanteligiblepatientswithmultiplemyeloma8vs4inductioncyclesthecarthadextrial AT deweerdtokke carfilzomibcombinedwiththalidomideandlowdosedexamethasoneforremissioninductionandconsolidationinnewlydiagnosedtransplanteligiblepatientswithmultiplemyeloma8vs4inductioncyclesthecarthadextrial AT minnemamoniquec carfilzomibcombinedwiththalidomideandlowdosedexamethasoneforremissioninductionandconsolidationinnewlydiagnosedtransplanteligiblepatientswithmultiplemyeloma8vs4inductioncyclesthecarthadextrial AT lonergansarah carfilzomibcombinedwiththalidomideandlowdosedexamethasoneforremissioninductionandconsolidationinnewlydiagnosedtransplanteligiblepatientswithmultiplemyeloma8vs4inductioncyclesthecarthadextrial AT palumboantonio carfilzomibcombinedwiththalidomideandlowdosedexamethasoneforremissioninductionandconsolidationinnewlydiagnosedtransplanteligiblepatientswithmultiplemyeloma8vs4inductioncyclesthecarthadextrial AT broijlannemiek carfilzomibcombinedwiththalidomideandlowdosedexamethasoneforremissioninductionandconsolidationinnewlydiagnosedtransplanteligiblepatientswithmultiplemyeloma8vs4inductioncyclesthecarthadextrial AT sonneveldpieter carfilzomibcombinedwiththalidomideandlowdosedexamethasoneforremissioninductionandconsolidationinnewlydiagnosedtransplanteligiblepatientswithmultiplemyeloma8vs4inductioncyclesthecarthadextrial |